Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
N/A N=30 Early Menopause Hormone Treatment and Cognition
Menopausal Syndrome
Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 2 N=92 The Effects of Reproductive Hormones on Mood and Behavior
Healthy Volunteers
Primary: Mean Beck Depression Inventory Score — 1.4; 1; 1.1 Units on a scale
Phase 3 N=501 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.72; -5.53; -6.26 VMS per day — p=<0.001
Phase 4 N=63 Raloxifene and Rimostil for Perimenopause-Related Depression
Perimenopausal Depression · Depression
Primary: Center for Epidemiologic Studies-Depression Scale (CES-D) — 27.4; 29.1; 28.8; 24.6 Units on a scale
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 4 N=46 Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Cyclical Change in Suicidal Ideation (SI) Severity — -.22; -.05; .25 units on a scale — p=.002
Phase 4 N=29 Impact of Hot Flashes on Sleep and Mood Disturbance
Menopause · Depression · Hot Flashes
Primary: Percent Change in Wake After Sleep Onset (WASO) — 62 percent change — p=0.007
N/A N=47 Females, Aging, Metabolism, and Exercise
Obesity
Primary: Change in Physical Activity Energy Expenditure (PAEE) — 74.5; -10.2; 61.0 kcal/day
Phase 3 N=527 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001
N/A N=187 Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
Hot Flashes
Primary: Hot Flash Frequency — 27.19; 68.26; 19.44; 62.32 hot flashes per week
Phase 4 N=64 Perimenopausal Effects of Estradiol on Reward Responsiveness
Perimenopausal Depression
Primary: Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment — .027; .043 percent signal change — p=.620
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
N/A N=53 Timing Estrogen After MenoPaUSe
Insulin Resistance
Primary: Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp) — 11.7; 11.5; 12.2; 10.7 mg/kg FFM/min
N/A N=17 Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Cognitive Impairment · Executive Dysfunction · Endothelial Dysfunction
Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight
Phase 2 N=37 Neuropeptide Treatment for Hot Flushes During the Menopause
Menopausal Flushing
Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001
N/A N=360 Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition
Menopausal Syndrome
Primary: Change From Baseline in Menopause Rating Scale Total Score — 6.3; 4.5 units on a scale — p=0.05
N/A N=1,036,294 A Study to Learn More About the Menopausal Hormone Therapies in Korea
Menopause · Bone Demineralization
Primary: Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year — 786616; 787425; 791890; 818749 Participants
Phase 4 N=79 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Phase 4 N=30 Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score — -.05; .35 units on a scale — p=.012
N/A N=92 Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
Arterial Stiffening · Aging · Menopause
Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1
Phase 4 N=47 Vortioxetine for Menopausal Depression
Depression · Menopause · Vasomotor Disturbance
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5) — -22.8 units on a scale
Phase 2 N=133 Homeopathic Treatment for Depression in Peri- and Postmenopausal Women
Moderate Depression · Menopausal and Postmenopausal Disorders
Primary: Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks. — 9.9; 11.7; 15 Units in Hamilton Scale — p=<0.05
Phase 2 N=73 A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
Major Depressive Disorder · Menopause · Perimenopause
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 26.2; 27.0; 15.7; 15.2 units on a scale — p=0.29
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05
Phase 2 N=102 Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score